Precision Medicine's Progress: Reports From The Front Lines
A roundtable of industry experts discuss how advances in biomarkers and personalized medicine will impact pharma R&D decisions and ultimately benefit patients (free with registration).
You may also be interested in...
Now backed by Roche, can Foundation Medicine continue to innovate in the delivery of molecular information in oncology and outpace the twin threats posed by the commoditization and regulation of genomic data?
The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.